Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00479089 · ClinicalTrials.gov registry record · Phase 2
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00479089: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00479089 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00479089, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Primary Objective: 1\. To compare the proportion of patients free from progression 9 months from the start of consolidation therapy with the combination of docetaxel and ZD1839 (Iressa) versus docetaxel alone. For the purposes of this protocol, "consolidation" therapy refers to treatment given at the time of maximal benefit from conventional front-line multi-agent chemotherapy. Secondary Objective: 1\. To compare time to progression (TTP), overall survival (OS) and cause-specific survival (CSS) in the two arms. For completeness, these will be reported both from the initiation of consolidation chemotherapy, and from the completion of induction chemotherapy.
Interventions
- DRUG Docetaxel
- DRUG Dexamethasone
- DRUG ZD1839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00479089
The ClinicalTrials.gov registry entry for NCT00479089 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00479089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00479089 about?
NCT00479089 is a clinical study titled "Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer". Primary Objective: 1\. To compare the proportion of patients free from progression 9 months from the start of consolidation therapy with the combination of docetaxel and ZD1839 (Iressa) versus docetaxel alone. For the purposes of this protocol, "consolidation" therapy refers to treatment given at t...
What is the current status of trial NCT00479089?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2004-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00479089?
The interventions under investigation include: Docetaxel (DRUG), Dexamethasone (DRUG), ZD1839 (DRUG).
Who is sponsoring clinical trial NCT00479089?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.